Add BrightSurf on Google Email

Leading cancer societies update clinical guideline on post-mastectomy radiation therapy

The American Society for Radiation Oncology, American Society of Clinical Oncology, and Society of Surgical Oncology jointly published a guideline outlining when post-mastectomy radiation therapy (PMRT) is appropriate based on new evidence. PMRT reduces cancer recurrence risk in patients with node-positive disease or high-risk features.

SourceAmerican Society for Radiation Oncology·JournalPractical Radiation Oncology·TypeSystematic review·DateSep 16, 2025

Study points out that a synthetic molecule helps reduce visceral fat and improve sleep

A synthetic molecule called Pep19 has been shown to reduce visceral fat and improve sleep quality in overweight adults, with no side effects observed. The study involved 24 volunteers who took either a placebo or Pep19 in capsules, and found a 17% reduction in visceral fat and improved sleep quality in those who received the molecule.

SourceFundação de Amparo à Pesquisa do Estado de São Paulo·JournalDiabetes/Metabolism Research and Reviews·DateAug 28, 2025

A patient’s own cartilage cells may be the key to help healing after hip surgery

A recent study by researchers at the University of Missouri has made a groundbreaking discovery using patient's own cartilage cells to aid in healing after hip surgery. The research team successfully cultured and expanded cartilage cells, or chondrocytes, in the lab, paving the way for future clinical applications.

SourceUniversity of Missouri-Columbia·JournalArchives of Orthopaedic and Trauma Surgery·TypeExperimental study·DateAug 19, 2025

An FDA-backed metric used to determine effectiveness of rectal cancer drugs may be unreliable, says new study

A new study published in JAMA Network Open found no statistical relationship between pathologic complete response (pCR) and overall survival in rectal cancer patients. This challenges the FDA's use of pCR as a surrogate endpoint for drug approval, which may lead to treatments being fast-tracked without evidence of improved long-term su...

SourceTulane University·JournalJAMA Network Open·DateJul 17, 2025

Anti-aging efficacy of 0.1 % pterostilbene skincare emulsion

A 0.1% pterostilbene skincare emulsion demonstrated remarkable improvements in skin elasticity, firmness, and reduced wrinkles over 28 days in a double-blind, split-face design study with 31 participants. The emulsion also increased epidermis layer thickness, enhanced collagen and elastic fibers, and minimized pores.

SourceKeAi Communications Co., Ltd.·JournalJournal of Dermatologic Science and Cosmetic Technology·TypeRandomized controlled/clinical trial·DateJul 16, 2025

New research in JNCCN offers reassurance about localized prostate cancer prognosis

A study of 62,839 people diagnosed with non-metastatic prostate cancer in Sweden found that those treated according to NCCN Guidelines were likely to survive their cancer for their remaining life-expectancy. Those with low- and intermediate-risk cancer were six times more likely to die of other causes than prostate cancer.

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·DateJul 10, 2025

Study findings help hone precision of proven CVD risk tool

Researchers at Sutter Health tested the performance of the American Heart Association's PREVENT equations in diverse Asian and Hispanic subgroups, showing accurate prediction of cardiovascular disease, atherosclerotic CVD, and heart failure events. The study findings aim to improve cardiovascular healthcare for all populations.

SourceSutter Health·JournalJAMA Cardiology·DateJul 10, 2025

New drug combination effective for T-cell lymphoma patients

Researchers at Mass General Brigham found a novel strategy to help patients control their disease, increasing eligibility for stem cell transplants. The combination of duvelisib and romidepsin was effective, tolerable, and safe for patients with relapsed/refractory peripheral and cutaneous T-cell lymphomas.

SourceMass General Brigham·JournalBlood Advances·TypeExperimental study·DateJul 1, 2025

Optimizing surgical strategies through a nationwide trial: insights from a Chinese Neurosurgical Journal study

A landmark national study in China identifies the most effective treatment strategies for unruptured brain aneurysms, analyzing over 874,000 clinical entries and 42,000 radiological scans. The trial aims to guide patient-specific treatment strategies and inform healthcare planning in China's aging population.

SourceChinese Neurosurgical Journal·JournalChinese Neurosurgical Journal·TypeRandomized controlled/clinical trial·DateJun 30, 2025

Groundbreaking cancer therapy clinical trial with US Department of Energy’s accelerator-produced actinium-225 set to begin this summer

The US Department of Energy's Isotope Program will supply a U.S. company with accelerator-produced actinium-225 for the first FDA-approved targeted cancer therapy clinical trial. This milestone marks a new pipeline for this lifesaving isotope, addressing its limited production due to complex manufacturing.

An international study validates the efficacy of a drug in adults with neurofibromatosis type 1

A phase 3 trial demonstrated the efficacy of selumetinib in reducing tumor size and alleviating pain in adults with neurofibromatosis type 1. The treatment was found to be effective in patients who received it from day one, as well as those who started it later, with significant reductions in tumor size and pain reported.

SourceGermans Trias i Pujol Research Institute·JournalThe Lancet·TypeRandomized controlled/clinical trial·DateJun 25, 2025

Technical refinement in airway surgery: Wrapping tracheobronchial anastomoses

A study of 95 patients found that wrapping autologous tissue materials around anastomoses after airway reconstruction significantly reduced short-term postoperative complications. This technique may offer a positive effect on the prognosis of patients undergoing complex tracheobronchial resection and reconstruction.

SourceNational Center for Respiratory Medicine·JournalTranslational Lung Cancer Research·TypeObservational study·DateJun 25, 2025

Primary care clinics can successfully use glucose monitors to help people with diabetes

A new study from the University of Colorado Anschutz Medical Campus shows that primary care clinics can effectively introduce continuous glucose monitors (CGMs) into their practices. The study found that both self-guided and virtual CGM initiation services were successful, regardless of clinic size or diabetes expertise.

New hope for patients with Werner syndrome

Researchers have discovered that nicotinamide riboside supplementation significantly improves NAD+ levels, reducing arterial stiffness, skin ulcer area, and kidney dysfunction. This breakthrough offers new hope for patients with Werner syndrome who lack effective treatment options.

SourceChiba University·JournalAging Cell·TypeExperimental study·DateJun 5, 2025

Combination finerenone and empagliflozin shows superior efficacy in reducing albuminuria in chronic kidney disease and type 2 diabetes patients

The CONFIDENCE trial demonstrates that combination therapy with finerenone and empagliflozin leads to significantly greater reductions in albuminuria than either agent alone. The study shows a 52% median reduction in urinary albumin-to-creatinine ratio, achieving the ADA-recommended target for 70% of patients.

SourceBeyond·JournalNew England Journal of Medicine·DateJun 5, 2025

Annual Alzheimer's clinical trials pipeline report shows increased reason for optimism

The annual Alzheimer's disease drug development pipeline report, led by Dr. Jeffrey Cummings, highlights an increase in active clinical trials and promising drugs, offering reason for optimism. The report assesses 138 drugs currently being studied and notes the growing importance of biomarkers in clinical trials.

SourceUniversity of Nevada, Las Vegas·JournalAlzheimer s & Dementia Translational Research & Clinical Interventions·TypeSystematic review·DateJun 3, 2025

ASCO: HER3-targeted antibody-drug conjugate (ADC) shows promise for treatment-resistant solid tumors

DB-1310, a HER3-targeted antibody-drug conjugate, has shown real potential as a new treatment option for patients with advanced solid tumors that have progressed after standard therapies. In an international clinical trial, DB-1310 demonstrated significant tumor shrinkage and delayed cancer growth in 44% of EGFR-mutant NSCLC patients.

Experimental Drug Development Centre granted US FDA fast track designation for antibody-drug conjugate EBC-129 to treat pancreatic ductal adenocarcinoma

The Experimental Drug Development Centre's EBC-129, an antibody-drug conjugate targeting pancreatic cancer, has received FDA fast track designation. The treatment is undergoing Phase 1 clinical trials and aims to provide new treatment options for patients with solid tumours.

UMGCCC researchers share new findings on link between lifetime alcohol use and colorectal cancer and more at AACR 2025

Researchers found that current drinkers who consumed 14 or more drinks per week had a 25% higher risk of colorectal cancer compared to those who drank less than one drink per week. The study also presented data on a novel immunotherapy treatment for acute myeloid leukemia, showing greater success and fewer side effects.

The European Society for Paediatric Endocrinology and the European Society of Endocrinology join together this weekend for their inaugural joint congress – “Connecting Endocrinology across the Life Course”

The inaugural Joint Congress brings together paediatric and adult endocrine specialists to learn from each other, collaborate, and celebrate endocrinology. Over 7,500 delegates from 100 countries attend the event to experience the latest research and developments.

One-week breast cancer radiotherapy proven as safe and effective as standard three-week treatment in 4,000-patient study over 10 years

A 10-year study confirms a one-week course of post-surgery radiotherapy is just as safe and effective as the traditional three-week regimen for early-stage breast cancer patients. This shorter schedule provides similar cancer control without additional long-term side effects.

SourceEuropean Society for Radiotherapy and Oncology (ESTRO)·JournalRadiotherapy and Oncology·TypeRandomized controlled/clinical trial·DateMay 7, 2025

Two-week radiotherapy proven as safe and effective as eight-week course for prostate cancer, after 10-year follow-up in phase III trial

A phase III clinical trial has shown that a two-and-a-half week course of precision radiotherapy is equally successful in beating prostate cancer as the standard eight-week approach. After 10 years, both options produced similar disease control rates and survival rates.

SourceEuropean Society for Radiotherapy and Oncology (ESTRO)·JournalRadiotherapy and Oncology·TypeRandomized controlled/clinical trial·DateMay 2, 2025

Building trust in artificial intelligence for healthcare: Lessons from clinical oncology

A new review advocates for building confidence in AI applications by implementing robust data governance frameworks, enhancing transparency, and involving stakeholders. The authors emphasize the importance of addressing ethical implications and ensuring equitable access to AI-driven innovations in clinical oncology.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalAI in Precision Oncology·TypeCommentary/editorial·DateApr 30, 2025

The potential oncogenic role of serum-derived hsa_circ_101555 as a non-invasive diagnostic/prognostic marker in patients with hepatocellular carcinoma

The study found that serum-derived hsa_circ_101555 showed excellent diagnostic accuracy in differentiating HCC patients from healthy controls. It also demonstrated a prognostic role in predicting tumor progression and response to therapy, with significant correlations with markers of liver inflammation and tumor features.

SourceXia & He Publishing Inc.·JournalGene Expression·DateApr 24, 2025